Concurrent ganirelix and follitropin beta therapy is an effective and safe regimen for ovulation induction in women with polycystic ovary syndrome

Fertility and Sterility

Volumn 79, Issue 3, 2003, Pages 603-607

  Elkind Hirsch, Karen E ^a,b   Webster, Bobby W ^b   Brown, Crystal P ^b   Vernon, Michael W ^b  

^a Woman's Ctr Fertil/Adv Repro M   (United States)

^b WOMAN S HOSPITAL   (United States)

Author keywords

Fasting glucose insulin ratio; Follitropin beta; Ganirelix; GnRH antagonist; PCOS; Polycystic ovary syndrome

Indexed keywords

CHORIONIC GONADOTROPIN; GANIRELIX; GLUCOSE; INSULIN; LUTEINIZING HORMONE; ORAL CONTRACEPTIVE AGENT; RECOMBINANT FOLLITROPIN;

ABORTION; ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIET RESTRICTION; DRUG EFFICACY; DRUG SAFETY; DRUG SCREENING; FEMALE; FEMALE INFERTILITY; GLUCOSE BLOOD LEVEL; HORMONE DETERMINATION; HUMAN; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; INSULIN SENSITIVITY; LUTEINIZING HORMONE BLOOD LEVEL; MALE; OVARY POLYCYSTIC DISEASE; OVULATION INDUCTION; PREGNANCY RATE; PRIORITY JOURNAL;

EID: 0037338176     PISSN: 00150282     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0015-0282(02)04696-4     Document Type: Article

References (23)

1. Devroey P. GnRH antagonists. Fertil Steril. 73:2000;15-17.
2. A double-blind, randomized, dose-finding study to assess the efficacy of the gonadotropin-releasing hormone antagonist Ganirelix (Org 37462) to prevent premature luteinizing hormone surges in women undergoing ovarian stimulation with recombinant follicle stimulating hormone (Puregon). Hum Reprod. 13:1998;3023-3031.
3. Albano C., Smitz J., Camus M., Riethmuller-Winzen H., Siebert-Weigel M., Diedrich K., et al. Hormonal profile during the follicular phase in cycles stimulated with a combination of human menopausal gonadotropin and gonadotropin releasing hormone antagonist (Centrorelix). Hum Reprod. 11:1996;2114-2118.
4. Fujimoto V.Y., Monroe S.E., Nelson L.R., Downey D., Jaffe R.B. Dose related suppression of serum luteinizing hormone in women by a potent new gonadotropin-releasing hormone antagonist (Ganirelix) administered by intranasal spray. Fertil Steril. 67:1997;469-473.
5. Efficacy and safety of ganirelix acetate versus leuprolide acetate in women undergoing controlled ovarian hyperstimulation. Fertil Steril. 75:2001;38-45.
6. Dor J., Shulman A., Levran D., Ben-Rafael Z., Rudak E., Mashiach S. The treatment of patients with polycystic ovarian syndrome by in-vitro fertilization and embryo transfer a comparison of results with those of patients with tubal infertility . Hum Reprod. 5:1990;816-818.
7. Shulman A., Dor J. In vitro fertilization treatment in patients with polycystic ovaries. J Assist Reprod Genet. 14:1997;7-10.
8. Tarlatzi B.C., Grimbizis G. The significance of high follicular-phase luteinizing hormone levels in the treatment of women with polycystic ovarian syndrome by in vitro fertilization. J Assist Reprod Genet. 14:1977;1-4.
9. Buyalos R.P., Lee C.T. Polycystic ovary syndrome pathophysiology and outcome with in vitro fertilization . Fertil Steril. 65:1996;1-10.
10. Homburg R., Levy T., Ben-Rafael Z. A comparative prospective study of conventional regimen with chronic low-dose administration of follicle stimulating hormone for anovulation associated with polycystic ovary syndrome. Fertil Steril. 63:1995;729-733.
11. Martin K.A., Hall J.E., Adams J., Crowley W.F. Comparison of exogenous gonadotropins and pulsatile GnRH for induction of ovulation in hypogonadotropic amenorrhea. J Clin Endocrinol Metab. 77:1993;125-129.
12. White D.M., Polson D.W., Kiddy D., Sagle P., Watson H., Gilling-Smith C., et al. Induction of ovulation with low-dose gonadotropins in polycystic ovary syndrome; an analysis of 109 pregnancies in 225 women. J Clin Endocrinol Metab. 81:1996;3821-3824.
13. Lidor A.L., Goldenberg M., Cohen S., Seidman D.S., Mashiach S., Rabinovici J. Management of women with polycystic ovary syndrome who experienced premature luteinization during clomiphene citrate treatment. Fertil Steril. 74:2000;749-752.
14. Dunaif A., Thomas A. Current concepts in the polycystic ovary syndrome. Annu Rev Med. 52:2001;401-419.
15. Legro R.S., Finegood D., Dunaif A. A fasting glucose to insulin ratio is a useful measure of insulin sensitivity in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 83:1998;2964-2968.
16. Rittmaster R.S. Differential suppression of testosterone and estradiol in hirsute women with the superactive gonadotropin-releasing agonist leuprolide. J Clin Endocrinol Metab. 67:1998;651-655.
17. World Health Organization. WHO lab manual for examination of human semen and semen-cervical mucus interaction. cambridge University PRess, Cambridge, UK: 1999.
18. Crosignani P.G., Ragni G., Parazzini F. Anthropometric indicators and response to gonadotropin for ovulation induction. Hum Reprod. 9:1994;420-423.
19. Chong A.P., Rafael R.W., Forte C.C. Influence of weight in the induction of ovulation with human menopausal gonadotropin and human chorionic gonadotropin. Fertil Steril. 46:1986;599-603.
20. Soderstrom-Anttila V., Foudila T., Hovatta O. A randomized comparative study of highly purified FSH and hMG for ovarian hyperstimulation in an oocyte donation programme. Hum Reprod. 11:1996;1864-1870.
21. Keningsberg D., Littman B.A., Williams R.F., Hodgen G.D. Medical hypophysectomy II. Variability of ovarian response to gonadotropin therapy . Fertil Steril. 42:1984;116-119.
22. Dodson W.C., Hughes C.L., Whitesides D.B., Haney A.F. The effect of leuprolide acetate on ovulation induction with human menopausal gonadotropins in polycystic ovary syndrome. J Clin Endocrinol Metab. 65:1987;95-99.
23. Lanzone A., Fulghesu A.M., Spina M.A., Apa R., Menini E., Caruso A., et al. Successful induction of ovulation and conception with combined gonadotropin-releasing hormone agonist plus highly purified follicle stimulating hormone in patients with polycystic ovarian disease. J Clin Endocrinol Metab. 65:1987;1253-1258.